NCT04066413 (Stardust) is a NA clinical trial of Standard infant formula in Healthy Growth, sponsored by FrieslandCampina.

Who is sponsoring NCT04066413?

NCT04066413 is sponsored by FrieslandCampina.

What drugs are being tested in NCT04066413?

Interventions in NCT04066413: Standard infant formula, Infant formula supplemented with HMO.

What condition does NCT04066413 study?

NCT04066413 studies Healthy Growth.

Is NCT04066413 still recruiting?

NCT04066413 is currently terminated. Last updated 28 September 2023.

Last reviewed 2023-09-28 · How we verify

NCT04066413: Stardust

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Growth and Tolerance Trial on Infant Formula With HMO

Terminated NA Last updated 28 September 2023

What this trial tests

NA trial testing Standard infant formula in Healthy Growth in 265 participants. Terminated before completion.

Timeline

23 September 2019

Primary endpoint
26 January 2023

26 January 2023

Quick facts

Lead sponsor	FrieslandCampina
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	265
Start date	23 September 2019
Primary completion	26 January 2023
Estimated completion	26 January 2023
Sites	1 location across United States

Drugs / interventions tested

Standard infant formula
Infant formula supplemented with HMO

Conditions studied

Healthy Growth — all drugs for Healthy Growth →

Sponsor

FrieslandCampina — full company profile →

Who can join

Under 1 Month, any sex, with Healthy Growth. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to compare growth of healthy infants fed an infant formula supplemented with a human milk oligosaccharide to that of infants on standard formula.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Standard infant formula

Trials testing the same drug.

NCT03456934 — Lower Protein Intake and Long-term Risk of Obesity and Cardiovascular Disease · NA · completed
NCT03067714 — A Clinical Study to Investigate the Effect of a Partially Hydrolysed Infant Formula With Added Synbiotics on Gut Microbi · Phase 3 · completed

Other FrieslandCampina trials

Trials by the same sponsor.

NCT07242508 — Efficacy of a New Infant Formula Composition on Gut Health in Infants · NA · not yet recruiting
NCT06251427 — Assessing the Effectiveness of a Multiple-micronutrient Fortified Maize Pap on the Nutrient Status of Nigerian School-ag · NA · completed
NCT05813769 — Dairy and Plant Amino Acid Uptake. An Explorative Study · NA · completed
NCT05670002 — Nutrition Intervention of Complementary Milk Feeding to Improve Linear Growth of at Risk and Stunted Children · NA · completed
NCT05418491 — The Prolonged Effect of Consumption of a Partially Hydrolyzed Infant Formula During the First 6 Months of Life on the De · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04066413 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by FrieslandCampina
Last refreshed: 28 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04066413.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing